ArticleArtificial organs2026
Extracorporeal Albumin Dialysis (OPAL) as Novel Therapeutic Bridging Option in Posthepatectomy Liver Failure.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundPosthepatectomy liver failure (PHLF) remains a major cause of mortality after liver resection, with limited therapeutic options. PHLF can be categorized into primary (small-for-size) and secondary forms, the latter resulting from complications such as sepsis or hemorrhage. Extracorporeal albumin dialysis (ECAD), including open albumin dialysis (OPAL), may support hepatic detoxification by removing albumin-bound toxins. While most studies focus on primary PHLF, data on secondary PHLF are scarce.
methodsThis retrospective cohort study includes all patients receiving OPAL after liver surgery until February 2026 at the Medical Center of the University of Freiburg, Germany. A detailed chart review was performed. The primary endpoint was bilirubin reduction per filter cycle. Survival and changes in laboratory parameters were analyzed as secondary endpoints.
resultsEighteen patients were included, predominantly with secondary PHLF (15/18, 83.3%). Sepsis was the leading cause of secondary liver failure (8/15, 53.3%), followed by hemorrhage (6/15, 40.0%). Median bilirubin reduction per filter cycle was 1.52 mg/dL (relative reduction 14.64%; p < 0.0001), with greater reductions at higher prefilter levels (p < 0.0001). Relative reductions were also observed in creatinine (16.84%) and urea (14.75%; both p < 0.0001). Platelet count and hemoglobin showed minor decreases, while MELD 3.0 scores improved modestly. Multiple consecutive filters did not increase overall bilirubin reduction. Thirty-day survival after surgery was 66.7% and 38.9% after OPAL initiation.
conclusionOPAL effectively reduces bilirubin levels and improves related parameters in PHLF. It may provide temporary detoxification support, particularly in secondary PHLF. Prospective studies are needed to assess its impact on patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.